Please ensure Javascript is enabled for purposes of website accessibility

NGM Biopharmaceuticals Reports a Successful NASH Trial

By Jim Crumly - Feb 24, 2020 at 3:11PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Strong results on multiple measures put the company's drug candidate firmly in the NASH discussion.

Shares of NGM Biopharmaceuticals (NGM -0.54%) soared 20% on a down day for the market after the company reported positive results from a trial of its lead drug for non-alcoholic steatohepatitis (NASH), aldafermin. NGM is a clinical-stage biotech company that had its initial public offering in April.

The trial was the fourth cohort of a phase 2 placebo-controlled study, in which 53 patients with biopsy-confirmed NASH took alderfermin daily for 24 weeks. The results indicated success on multiple measures, meeting the primary endpoint of liver fat reduction as well as secondary and exploratory endpoints for liver histology and disease activity.

Image of a liver above hand of a physician.

Image source: Getty Images.

Alderfermin reduced liver fat content by an average of 39%, compared with 13% for the placebo group, with 66% of the treated group achieving greater than a 30% reduction versus 29% of patients receiving the placebo.

But perhaps even more significant were the results for measures that the U.S. Food and Drug Administration (FDA) has indicated will be important for winning accelerated approval of NASH drugs -- 38% of the patients on alderfermin had improvement in liver fibrosis with no worsening of NASH, compared with 18% on placebo. And 24% of patients taking the drug had resolution of NASH, meaning little or no liver inflammation or ballooning, without worsening of fibrosis, versus 9% of the placebo group. Better still, 22% of the trial subjects achieved both fibrosis improvement and NASH resolution, compared with none taking the placebo.

Although the trial was relatively small and NGM is still years away from potential approval of alderfermin, the results pointed to the possibility of its superiority to Ocaliva from Intercept Pharmaceuticals (ICPT 5.15%). Intercept is leading the race to bring a NASH drug to market, and expects a decision by the FDA on Ocaliva by June 26.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

NGM Biopharmaceuticals, Inc. Stock Quote
NGM Biopharmaceuticals, Inc.
NGM
$12.85 (-0.54%) $0.07
Intercept Pharmaceuticals Stock Quote
Intercept Pharmaceuticals
ICPT
$13.67 (5.15%) $0.67

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
319%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.